bioAffinity Technologies, Inc. Warrant (BIAFW) Financials
Newest figures come from the 10-Q for Q2 FY2026, filed Aug 7, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the BIAFW SEC filings page.
bioAffinity Technologies, Inc. Warrant (BIAFW) reported $5.9M in revenue over the twelve months to Jun 30, 2026, down 23.2% from the prior twelve months. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 5 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
The business is shrinking while largely fixed overhead deepens losses, and financing—not operations—has supported its balance sheet.
FY2025 revenue was34.2% below FY2024, while operating margin reached-171.6% . SG&A stayed near$9.9M as R&D fell to$1.4M , indicating overhead—not development spending—was the main reason costs failed to flex with demand.
Cash conversion is weak: operating cash flow of
The current ratio recovered from 0.9x to 2.6x, but operating cash flow remained negative. That improvement coincided with
Financial Health Signals
Scored against emerging companies for FY2025. Each of the six dimensions is a percentile rank within that peer group; the overall is their average, with missing dimensions counted as zero out of six. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →
Health score ≠ stock price. This rates the quality of bioAffinity Technologies, Inc. Warrant's business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.
bioAffinity Technologies, Inc. Warrant held $6.4M in cash, cash equivalents and investments at the end of fiscal year 2025, and its operations used $9.3M of cash that year. Cash Runway ranks emerging companies on the size of that balance against the outflow behind it, and bioAffinity Technologies, Inc. Warrant scores 26/100 among other emerging companies.
bioAffinity Technologies, Inc. Warrant had 4M shares outstanding at the end of fiscal year 2025. Dilution ranks emerging companies on how fast that count has grown over three years, where a slower rise is the better one, and bioAffinity Technologies, Inc. Warrant scores 83/100 among other emerging companies.
bioAffinity Technologies, Inc. Warrant spent $1.4M on research and development in fiscal year 2025, which was 8.3% of its operating costs that year. R&D Intensity ranks emerging companies on the share of operating costs that goes into research, and bioAffinity Technologies, Inc. Warrant scores 33/100 among other emerging companies.
bioAffinity Technologies, Inc. Warrant reported revenue of $6.2M in fiscal year 2025, against $9.4M in fiscal year 2024. Revenue Progress ranks emerging companies on the three-year path of that line, and bioAffinity Technologies, Inc. Warrant scores 28/100 among other emerging companies.
bioAffinity Technologies, Inc. Warrant's operations used $9.3M of cash in fiscal year 2025, against $7.3M used in fiscal year 2024. Burn Trend ranks emerging companies on which way that figure has moved over three years, and bioAffinity Technologies, Inc. Warrant scores 27/100 among other emerging companies.
bioAffinity Technologies, Inc. Warrant's cash, cash equivalents and investments came to $6.4M at the end of fiscal year 2025, against $3.7M of total liabilities. Balance Sheet ranks emerging companies on that comparison, and bioAffinity Technologies, Inc. Warrant scores 71/100 among other emerging companies.
bioAffinity Technologies, Inc. Warrant passes 4 of 7 computable financial strength tests (2 of the nine could not be computed from available data). 2 of 4 profitability signals pass, all 2 leverage/liquidity signals pass, neither operating efficiency signal passes.
bioAffinity Technologies, Inc. Warrant reported a net loss of $14.9M while operations used $9.3M of cash. With neither figure positive, the ratio between the two carries no quality signal.
bioAffinity Technologies, Inc. Warrant reported an operating loss of $10.6M against $44K in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations.
Key Financial Metrics
Earnings & Revenue
bioAffinity Technologies, Inc. Warrant generated $1.5M in revenue in Q2 2026. This represents an increase of 19.0% from the same quarter a year earlier. Against the prior quarter it is up 11.8%.
bioAffinity Technologies, Inc. Warrant's EBITDA was -$3.3M in Q2 2026, measuring earnings before interest, taxes, depreciation, and amortization. This represents a decrease of 36.3% from the same quarter a year earlier. Against the prior quarter it is up 6.5%.
bioAffinity Technologies, Inc. Warrant reported -$3.4M in net income in Q2 2026. This represents an increase of 17.1% from the same quarter a year earlier. Against the prior quarter it is up 7.3%.
bioAffinity Technologies, Inc. Warrant earned -$0.64 per diluted share (EPS) in Q2 2026. Against the prior quarter it is up 21.0%.
Cash & Balance Sheet
bioAffinity Technologies, Inc. Warrant recorded an outflow of $3.3M in free cash flow in Q2 2026, representing a cash shortfall after capex. This represents a decrease of 23.7% from the same quarter a year earlier. Against the prior quarter it is down 1.8%.
bioAffinity Technologies, Inc. Warrant held $2.4M in cash as of Q2 2026; long-term debt is not reported for that period.
Not reported for Q2 2026.
Margins & Returns
bioAffinity Technologies, Inc. Warrant's ROE was -89.3% in Q2 2026, measuring profit generated per dollar of shareholder equity. Against the prior quarter it is up 10.2 percentage points.
Not reported for Q2 2026.
Not shown for Q2 2026: the reported ratio is below -100.0% of revenue, so it does not read as a share of revenue.
Not shown for Q2 2026: the reported ratio is below -100.0% of revenue, so it does not read as a share of revenue.
Capital Allocation
bioAffinity Technologies, Inc. Warrant invested $362K in research and development in Q2 2026. This represents an increase of 16.1% from the same quarter a year earlier. Against the prior quarter it is up 3.4%.
bioAffinity Technologies, Inc. Warrant invested $90K in capex in Q2 2026, funding long-term assets and infrastructure. This represents an increase of 570.1% from the same quarter a year earlier. Against the prior quarter it is up 1488.7%.
Not reported for Q2 2026.
BIAFW Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Revenue | $1.5M+19.0% | $1.4M-27.1% | $1.6M-27.8% | $1.4M-38.5% | $1.3M-47.1% | $1.9M-23.0% | $2.2M-70.9% | $2.4M+682.8% |
| R&D Expenses | $362K+16.1% | $350K-4.8% | $374K-4.3% | $331K+20.4% | $311K-22.6% | $367K-6.7% | $391K-9.7% | $274K-16.9% |
| SG&A Expenses | $2.9M+29.1% | $3.2M+32.2% | $3.0M+4.0% | $2.2M-6.6% | $2.2M-10.4% | $2.5M+12.2% | $2.9M+31.9% | $2.4M+16.8% |
| Operating Income | -$3.3M-32.6% | -$3.6M-37.7% | -$3.1M-6.5% | -$2.3M-16.2% | -$2.5M-20.5% | -$2.6M-35.1% | -$2.9M-25.8% | -$2.0M+14.0% |
| EBITDA | -$3.3M-36.3% | -$3.5M-41.7% | -$3.0M-7.9% | -$2.2M-19.6% | -$2.4M-24.0% | -$2.5M-37.7% | -$2.8M-27.3% | -$1.8M+18.5% |
| Interest Expense | $12K+11.7% | $15K-4.9% | $13K-47.8% | $5K-75.2% | $10K-53.0% | $15K-34.2% | $25K-1.1% | $22K+146.2% |
| Income Tax | N/A | N/A | $3K | $3K+24.3% | $29K+434.9% | $9K+136.8% | $0-100.0% | $3K+11.6% |
| Net Income | -$3.4M+17.1% | -$3.6M-36.5% | -$3.1M-5.7% | -$5.1M-152.4% | -$4.1M-92.4% | -$2.7M-35.6% | -$3.0M-25.0% | -$2.0M+12.7% |
| EPS (Basic) | -$0.64+87.4% | -$0.81+83.1% | -$1.11+82.3% | -$4.74+2.1% | -$5.07-2568.4% | -$4.80-2300.0% | -$6.28-2315.4% | -$4.84-1761.5% |
| EPS (Diluted) | -$0.64 | -$0.81 | -$1.11 | -$4.74 | -$5.07 | -$4.80 | -$6.28 | -$4.84 |
| Diluted Shares (Avg) | 5M | 4M | N/A | 1M | 800,637 | 541,841 | N/A | 412,936 |
Not reported in any period shown, so not listed: Cost of Revenue, Gross Profit.
BIAFW Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $7.6M+60.4% | $7.9M+43.2% | $11.0M+68.3% | $11.5M+76.2% | $4.8M-28.6% | $5.5M-31.1% | $6.5M-20.8% | $6.6M-35.7% |
| Current Assets | $3.9M+131.6% | $4.3M+132.9% | $7.6M+180.7% | $8.6M+237.9% | $1.7M-37.7% | $1.9M-52.6% | $2.7M-32.2% | $2.5M-57.6% |
| Cash & Equivalents | $2.4M+202.6% | $3.1M+596.7% | $6.4M+483.5% | $7.7M+913.7% | $803K+0.2% | $445K-81.9% | $1.1M-60.8% | $757K-83.2% |
| Short-Term Investments | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Inventory | $82K+87.3% | $78K+100.8% | $54K+94.0% | $35K+38.9% | $44K+47.7% | $39K+308.8% | $28K+49.4% | $25K+156.0% |
| Long-Term Investments | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Goodwill | $1.4M0.0% | $1.4M0.0% | $1.4M0.0% | $1.4M0.0% | $1.4M0.0% | $1.4M0.0% | $1.4M0.0% | $1.4M+22.3% |
| Total Liabilities | $3.9M-44.1% | $4.3M+4.3% | $3.7M-5.8% | $2.6M-22.9% | $6.9M+113.7% | $4.1M+47.1% | $3.9M+16.2% | $3.4M+7.4% |
| Current Liabilities | $2.7M+3.6% | $3.2M-6.7% | $2.9M-6.4% | $2.4M-5.3% | $2.6M+11.3% | $3.4M+92.8% | $3.1M+38.1% | $2.5M+27.2% |
| Non-Current Liabilities | $1.2M-72.8% | $1.1M+58.7% | $777K-3.7% | $285K-69.7% | $4.3M+379.2% | $692K-32.2% | $807K-27.9% | $940K-24.0% |
| Total Equity | $3.8M+276.4% | $3.6M+153.4% | $7.3M+179.7% | $8.9M+185.2% | -$2.1M-162.2% | $1.4M-72.6% | $2.6M-46.4% | $3.1M-55.4% |
| Retained Earnings | -$75.6M-25.2% | -$72.2M-28.2% | -$68.6M-27.8% | -$65.4M-29.1% | -$60.4M-24.0% | -$56.3M-20.9% | -$53.6M-20.3% | -$50.7M-20.0% |
Not reported in any period shown, so not listed: Accounts Receivable, Long-Term Debt.
BIAFW Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$3.2M-20.9% | -$3.2M-96.6% | -$2.6M-52.6% | -$2.5M-45.1% | -$2.6M-72.7% | -$1.6M+30.0% | -$1.7M-3.8% | -$1.7M-11.5% |
| Depreciation & Amortization | $62K-45.6% | $115K-25.9% | $124K-19.5% | $113K-25.1% | $113K-25.0% | $155K+3.3% | $154K+3.3% | $151K+162.8% |
| Stock-Based Compensation | N/A | $14K-95.6% | N/A | $67K-63.8% | $212K-26.3% | $327K+15.1% | N/A | $186K+117.8% |
| Capital Expenditures | $90K+570.1% | $6K-88.8% | $10.0% | -$4K-61.3% | $13K-52.5% | $51K+22.7% | $1-100.0% | $9K+5468.0% |
| Free Cash Flow | -$3.3M-23.7% | -$3.2M-91.0% | -$2.6M-52.6% | -$2.5M-44.5% | -$2.7M-70.5% | -$1.7M+29.1% | -$1.7M-2.9% | -$1.7M-12.1% |
| Investing Cash Flow | -$90K-570.1% | -$6K+88.8% | -$10.0% | $4K+138.7% | -$13K+52.5% | -$51K-22.7% | -$1-100.0% | -$9K+99.6% |
| Financing Cash Flow | $2.6M-13.1% | -$119K-111.5% | $1.3M-33.8% | $9.3M+458.2% | $3.0M+3412.1% | $1.0M-48.9% | $2.0M+2488.9% | $1.7M+3397.2% |
Not reported in any period shown, so not listed: Dividends Paid, Share Buybacks.
BIAFW Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Operating Margin | -220.8% | -267.6% | -196.9% | -158.6% | -198.2% | -141.7% | -133.5% | -84.0% |
| Net Margin | -222.8% | -268.6% | -197.0% | -349.3% | -319.9% | -143.5% | -134.4% | -85.1% |
| Return on Equity | -89.3% | -99.6%+85.3pp | -43.1%+70.9pp | -56.7%+7.4pp | N/A | -184.8%-147.5pp | -114.0%-65.1pp | -64.1%-31.4pp |
| Return on Assets | -44.2%+41.3pp | -45.7%+2.3pp | -28.6%+16.9pp | -43.8%-13.2pp | -85.5%-53.8pp | -48.0%-23.6pp | -45.6%-16.7pp | -30.5%-8.1pp |
| Current Ratio | 1.44+0.8x | 1.36+0.8x | 2.60+1.7x | 3.65+2.6x | 0.64-0.5x | 0.55-1.7x | 0.87-0.9x | 1.02-2.0x |
| Debt-to-Equity | 1.02 | 1.17-1.7x | 0.51-1.0x | 0.30-0.8x | N/A | 2.85+2.3x | 1.50+0.8x | 1.10+0.6x |
| Asset Turnover | 0.20-0.1x | 0.17-0.2x | 0.15-0.2x | 0.13-0.2x | 0.27-0.1x | 0.330.0x | 0.34-0.6x | 0.36+0.3x |
| FCF Margin | -217.9% | -239.2% | -160.7% | -171.8% | -209.6% | -91.3%+7.9pp | -76.0%-54.5pp | -73.1% |
Not reported in any period shown, so not listed: Gross Margin.
Reported as filed but not readable as a share of revenue in the periods where the ratio runs further from zero than a revenue base allows; no change figure is given where either compared period is one of those: Operating Margin, Net Margin, FCF Margin.
Similar Companies
Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it.
| Company | Fiscal year | Revenue | Net income | Net margin | Market cap | Health score |
|---|---|---|---|---|---|---|
| bioAffinity Technologies, Inc. Warrant BIAFW | FY2025 | $6.2M | -$14.9M | N/A | N/A | 45/100 |
| bioAffinity Technologies, Inc. BIAF | FY2025 | $6.2M | -$14.9M | N/A | $4.6M | 45/100 |
| Precipio, Inc. PRPO | FY2025 | $24.0M | -$363K | -1.5% | $38.0M | 59/100 |
| Advanced Biomed Inc. ADVB | FY2026 | $128K | $6.7M | N/A | $6.2M | — |
| Mainz Biomed N.V. MYNZ | FY2025 | $537K | -$16.2M | N/A | $10.6M | — |
| Check-Cap Ltd. CHEK | FY2025 | N/A | $4.1M | N/A | $4.0M | — |
Where bioAffinity Technologies, Inc. Warrant Ranks
Frequently Asked Questions
What is bioAffinity Technologies, Inc. Warrant's annual revenue?
bioAffinity Technologies, Inc. Warrant (BIAFW) reported $6.2M in total revenue for fiscal year 2025. This represents a -34.2% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is bioAffinity Technologies, Inc. Warrant's revenue growing?
bioAffinity Technologies, Inc. Warrant (BIAFW) revenue declined by 34.2% year-over-year, from $9.4M to $6.2M in fiscal year 2025.
Is bioAffinity Technologies, Inc. Warrant profitable?
No, bioAffinity Technologies, Inc. Warrant (BIAFW) reported a net income of -$14.9M in fiscal year 2025.
What is bioAffinity Technologies, Inc. Warrant's EBITDA?
bioAffinity Technologies, Inc. Warrant (BIAFW) had EBITDA of -$10.1M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
What is bioAffinity Technologies, Inc. Warrant's return on equity (ROE)?
bioAffinity Technologies, Inc. Warrant (BIAFW) has a return on equity of -204.9% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
What is bioAffinity Technologies, Inc. Warrant's free cash flow?
bioAffinity Technologies, Inc. Warrant (BIAFW) recorded an outflow of $9.4M in free cash flow during fiscal year 2025. This represents a -27.9% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is bioAffinity Technologies, Inc. Warrant's operating cash flow?
bioAffinity Technologies, Inc. Warrant (BIAFW) recorded an outflow of $9.3M in operating cash flow during fiscal year 2025, representing cash used by core business activities.
What are bioAffinity Technologies, Inc. Warrant's total assets?
bioAffinity Technologies, Inc. Warrant (BIAFW) had $11.0M in total assets as of fiscal year 2025, including both current and long-term assets.
What are bioAffinity Technologies, Inc. Warrant's capital expenditures?
bioAffinity Technologies, Inc. Warrant (BIAFW) invested $61K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.
How much does bioAffinity Technologies, Inc. Warrant spend on research and development?
bioAffinity Technologies, Inc. Warrant (BIAFW) invested $1.4M in research and development during fiscal year 2025.
What is bioAffinity Technologies, Inc. Warrant's current ratio?
bioAffinity Technologies, Inc. Warrant (BIAFW) had a current ratio of 2.60 as of fiscal year 2025, which is generally considered healthy.
What is bioAffinity Technologies, Inc. Warrant's debt-to-equity ratio?
bioAffinity Technologies, Inc. Warrant (BIAFW) had a debt-to-equity ratio of 0.51 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is bioAffinity Technologies, Inc. Warrant's return on assets (ROA)?
bioAffinity Technologies, Inc. Warrant (BIAFW) had a return on assets of -136.0% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
How does bioAffinity Technologies, Inc. Warrant's liquidity compare with its operating cash outflow?
At the end of fiscal year 2025, bioAffinity Technologies, Inc. Warrant (BIAFW) held $6.4M in cash, cash equivalents and investments, and reported an operating cash outflow of $9.3M over that year. Dividing the one by the other, the reported balance equals about 8 months of the outflow reported that year. This is arithmetic over figures already filed, not a projection: it assumes nothing about future spending, financing or operations.
What is bioAffinity Technologies, Inc. Warrant's Piotroski F-Score?
bioAffinity Technologies, Inc. Warrant (BIAFW) has a Piotroski F-Score of 4 out of 7 computable signals; 2 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are bioAffinity Technologies, Inc. Warrant's earnings high quality?
bioAffinity Technologies, Inc. Warrant (BIAFW) reported a net loss of $14.9M while operations used $9.3M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
Can bioAffinity Technologies, Inc. Warrant cover its interest payments?
bioAffinity Technologies, Inc. Warrant (BIAFW) reported an operating loss of $10.6M against $44K in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.
How financially healthy is bioAffinity Technologies, Inc. Warrant?
bioAffinity Technologies, Inc. Warrant (BIAFW) scores 45 out of 100 on our Financial Health Score, indicating moderate standing within its emerging companies peer group. The score is a 0-100 composite of six dimensions (Cash Runway, Dilution, R&D Intensity, Revenue Progress, Burn Trend, Balance Sheet), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.